재조합 백신 시장 규모, 점유율, 성장 분석 : 종류별, 질환별, 최종사용자별, 유통 경로별, 지역별 - 업계 예측(2026-2033년)

Recombinant Vaccines Market size was valued at USD 11.2 Billion in 2024 and is poised to grow from USD 12.47 Billion in 2025 to USD 29.58 Billion by 2033, growing at a CAGR of 11.4% during the forecast period (2026-2033).

Recombinant vaccines represent a paradigm shift in immunization strategies, moving away from conventional methods that relied on pathogen exposure. Leveraging advancements in genetic engineering, genomics, and recombinant DNA technologies, these vaccines are designed in controlled laboratory settings, employing genetic screening to mitigate risks associated with infectious diseases. This innovative approach enhances both the efficacy and safety of vaccines, marking a substantial improvement in vaccine development. By allowing for a more precise and tailored immunization process, recombinant vaccines are positioned to address various health challenges effectively. This evolution not only strengthens public health responses but also highlights the potential for ongoing advancements in vaccine technology, making it an exciting area in the healthcare market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Recombinant Vaccines market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Recombinant Vaccines Market Segments Analysis

Global Recombinant Vaccines Market is segmented by Type, Disease, End User, Distribution Channel and region. Based on Type, the market is segmented into Subunit recombinant vaccines, Attenuated recombinant vaccines and Vector recombinant vaccines. Based on Disease, the market is segmented into Pneumococcal Disease, Cancer, Hepatitis B, Influenza, DPT and Others. Based on End User, the market is segmented into Pediatric, Adult and Geriatric. Based on Distribution Channel, the market is segmented into Hospital & Retail Pharmacies and Government Suppliers. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Recombinant Vaccines Market

The growth of the recombinant vaccines market is significantly driven by the widespread adoption of recombinant technology, which greatly improves the safety and effectiveness of vaccines for patients. This technology allows for the rapid and large-scale production of vaccines, reducing supply shortages and ensuring availability. Additionally, recombinant vaccines are free from infectious viral particles, making them safer for those with weakened immune systems. The positive attributes of these vaccines have motivated manufacturers to concentrate on innovating new products aimed at combating viral diseases. This focus involves utilizing advanced DNA technology, genomics, and other state-of-the-art biotechnological approaches to develop vaccines that are not only more effective but also safer overall.

Restraints in the Recombinant Vaccines Market

The Recombinant Vaccines market faces several challenges that hinder its growth, with the high cost per dose being a primary obstacle. Although global health organizations are actively working to enhance vaccination efforts by distributing millions of doses worldwide, the expensive nature of these vaccines remains a significant barrier for various populations. Even as initiatives aim to improve access and reach underserved areas, many regions still experience difficulties in obtaining vaccines due to their prohibitive costs. This economic factor continues to be a major limitation, impacting the overall effectiveness of vaccination programs across different communities.

Market Trends of the Recombinant Vaccines Market

The Recombinant Vaccines market is experiencing significant growth driven by the rising global incidence of infectious diseases and the urgent need for effective immunization strategies. The heightened vulnerability of specific demographics, particularly the elderly and pediatric populations, amplifies the demand for these advanced vaccines. Organizations like UNICEF and PAHO are pivotal in facilitating the swift distribution of vaccine doses, addressing emergency healthcare needs, and enhancing community resilience against various pathogens. This robust engagement from international bodies not only mitigates disease transmission but also fosters innovation and development within the recombinant vaccine sector, positioning it as a critical component of modern healthcare strategies.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Recombinant Vaccines Market Size by Type & CAGR (2026-2033)

• Market Overview
• Subunit recombinant vaccines
• Attenuated recombinant vaccines
• Vector recombinant vaccines

Global Recombinant Vaccines Market Size by Disease & CAGR (2026-2033)

• Market Overview
• Pneumococcal Disease
• Cancer
• Hepatitis B
• Influenza
• DPT
• Others

Global Recombinant Vaccines Market Size by End User & CAGR (2026-2033)

• Market Overview
• Pediatric
• Adult
• Geriatric

Global Recombinant Vaccines Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital & Retail Pharmacies
• Government Suppliers

Global Recombinant Vaccines Market Size & CAGR (2026-2033)

• North America (Type, Disease, End User, Distribution Channel)
  • US
  • Canada
• Europe (Type, Disease, End User, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Disease, End User, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Disease, End User, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Disease, End User, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (GSK) (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Moderna, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novavax, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bavarian Nordic A/S (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioNTech SE (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vaxart, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Transgene S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GeoVax Labs, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vaxcyte, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Green Cross Corporation (GC Biopharma) (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bharat Biotech International Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shantha Biotechnics Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Valneva SE (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Inovio Pharmaceuticals, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sinovac Biotech Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations